Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.